Samantha L Sampson

List of Publications by Year
in descending order

54 papers	2,459 citations	226546 25 h-index	214353 47 g-index
56 all docs	56 docs citations	56 times ranked	3856 citing authors

#	Article	IF	Citations
1	Discovery and biological evaluation of an adamantyl-amide derivative with likely MmpL3 inhibitory activity. Tuberculosis, 2023, 141, 102350.	2.0	1
2	Localization of EccA3 at the growing pole in Mycobacterium smegmatis. BMC Microbiology, 2022, 22, 140.	3.4	1
3	Evidence, Challenges, and Knowledge Gaps Regarding Latent Tuberculosis in Animals. Microorganisms, 2022, 10, 1845.	3.6	3
4	Antimycobacterial Activity, Synergism, and Mechanism of Action Evaluation of Novel Polycyclic Amines against Mycobacterium tuberculosis. Advances in Pharmacological and Pharmaceutical Sciences, 2021, 2021, 1-8.	1.4	1
5	PPE38-Secretion-Dependent Proteins of M. tuberculosis Alter NF-kB Signalling and Inflammatory Responses in Macrophages. Frontiers in Immunology, 2021, 12, 702359.	4.9	4
6	Drug resistant tuberculosis cases from the Copperbelt province and Northern regions of Zambia: Genetic diversity, demographic and clinical characteristics. Tuberculosis, 2021, 130, 102122.	2.0	1
7	Inhaled particulate matter affects immune responsiveness of human lung phagocytes to mycobacteria. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2021, 321, L566-L575.	3.0	1
8	In silico repurposing of a Novobiocin derivative for activity against latency associated Mycobacterium tuberculosis drug target nicotinate-nucleotide adenylyl transferase (Rv2421c). PLoS ONE, 2021, 16, e0259348.	2.5	5
9	Identification of gene fusion events in Mycobacterium tuberculosis that encode chimeric proteins. NAR Genomics and Bioinformatics, 2020, 2, lqaa033.	3.2	3
10	Mechanisms of Drug-Induced Tolerance in Mycobacterium tuberculosis. Clinical Microbiology Reviews, 2020, 34, .	14.4	75
11	Recent Developments in the Application of Flow Cytometry to Advance our Understanding of <scp><i>Mycobacterium</i></scp><scp><i>tuberculosis</i></scp> Physiology and Pathogenesis. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2020, 97, 683-693.	2.0	15
12	Molecular epidemiology of drug resistant Mycobacterium tuberculosis in Africa: a systematic review. BMC Infectious Diseases, 2020, 20, 344.	3.0	21
13	ProVision: a web-based platform for rapid analysis of proteomics data processed by MaxQuant. Bioinformatics, 2020, 36, 4965-4967.	4.2	26
14	Identifying nucleic acid-associated proteins in Mycobacterium smegmatis by mass spectrometry-based proteomics. BMC Molecular and Cell Biology, 2020, 21, 19.	2.1	8
15	Spatial distribution of Mycobacterium Tuberculosis in metropolitan Harare, Zimbabwe. PLoS ONE, 2020, 15, e0231637.	2.5	17
16	Whole genome sequencing provides additional insights into recurrent tuberculosis classified as endogenous reactivation by IS6110 DNA fingerprinting. Infection, Genetics and Evolution, 2019, 75, 103948.	2.3	16
17	Comprehensive Characterization of the Attenuated Double Auxotroph Mycobacterium tuberculosisÎ”leuDÎ”panCD as an Alternative to H37Rv. Frontiers in Microbiology, 2019, 10, 1922.	3.6	37
18	Evolution of rifampicin treatment for tuberculosis. Infection, Genetics and Evolution, 2019, 74, 103937.	2.3	74

#	Article	IF	Citations
19	Structure based identification of novel inhibitors against ATP synthase of Mycobacterium tuberculosis: A combined in silico and in vitro study. International Journal of Biological Macromolecules, 2019, 135, 582-590.	7.7	4
20	Mycobacterium Tuberculosis and Interactions with the Host Immune System: Opportunities for Nanoparticle Based Immunotherapeutics and Vaccines. Pharmaceutical Research, 2019, 36, 8.	3.6	21
21	Mycobacterial nucleoid associated proteins: An added dimension in gene regulation. Tuberculosis, 2018, 108, 169-177.	2.0	27
22	Geospatial distribution of Mycobacterium tuberculosis genotypes in Africa. PLoS ONE, 2018, 13, e0200632.	2.5	57
23	Implications of Chromosomal Mutations for Mycobacterial Drug Resistance. , 2017, , 233-262.		1
24	Proteogenomic Investigation of Strain Variation in Clinical <i>Mycobacterium tuberculosis</i> Isolates. Journal of Proteome Research, 2017, 16, 3841-3851.	3.8	27
25	Small Molecule Efflux Pump Inhibitors in Mycobacterium tuberculosis: A Rational Drug Design Perspective. Mini-Reviews in Medicinal Chemistry, 2017, 18, 72-86.	2.6	16
26	Versatility of 7-Substituted Coumarin Molecules as Antimycobacterial Agents, Neuronal Enzyme Inhibitors and Neuroprotective Agents. Molecules, 2017, 22, 1644.	3.9	23
27	Two promoters in the esx-3 gene cluster of Mycobacterium smegmatis respond inversely to different iron concentrations in vitro. BMC Research Notes, 2017, 10, 426.	1.4	3
28	Recombination in pe/ppe genes contributes to genetic variation in Mycobacterium tuberculosis lineages. BMC Genomics, 2016, 17, 151.	2.9	67
29	<scp>TB</scp> Vaccine Assessment. , 2016, , 91-110.		0
30	Mammalian cell cultures as models for Mycobacterium tuberculosis â€“human immunodeficiency virus (HIV) interaction studies: A review. Asian Pacific Journal of Tropical Medicine, 2016, 9, 832-838.	0.9	5
31	Prevalence of pyrazinamide resistance across the spectrum of drug resistant phenotypes of Mycobacterium tuberculosis. Tuberculosis, 2016, 99, 128-130.	2.0	17
32	Strength in Diversity: Hidden Genetic Depths of Mycobacterium tuberculosis. Trends in Microbiology, 2016, 24, 82-84.	7.7	3
33	Efflux pump inhibitors: targeting mycobacterial efflux systems to enhance TB therapy. Journal of Antimicrobial Chemotherapy, 2016, 71, 17-26.	3.2	129
34	Elucidating population-wide mycobacterial replication dynamics at the single-cell level. Microbiology (United Kingdom), 2016, 162, 966-978.	1.8	61
35	A Global Perspective on Pyrazinamide Resistance: Systematic Review and Meta-Analysis. PLoS ONE, 2015, 10, e0133869.	2.5	111
36	Iron acquisition strategies in mycobacteria. Tuberculosis, 2015, 95, 123-130.	2.0	55

#	Article	IF	Citations
37	Phosphoproteomics analysis of a clinical Mycobacterium tuberculosis Beijing isolate: expanding the mycobacterial phosphoproteome catalog. Frontiers in Microbiology, 2015, 6, 6.	3.6	65
38	Mycobacterium tuberculosis <i>pncA</i> Polymorphisms That Do Not Confer Pyrazinamide Resistance at a Breakpoint Concentration of 100 Micrograms per Milliliter in MGIT. Journal of Clinical Microbiology, 2015, 53, 3633-3635.	4.4	35
39	Whole genome sequence analysis of Mycobacterium suricattae. Tuberculosis, 2015, 95, 682-688.	2.0	54
40	Cell Electrospinning: An In Vitro and In Vivo Study. Small, 2014, 10, 78-82.	11.2	83
41	Rapid in vivo assessment of drug efficacy against Mycobacterium tuberculosis using an improved firefly luciferase. Journal of Antimicrobial Chemotherapy, 2013, 68, 2118-2127.	3.2	60
42	Post-genomic Antigen Discovery: Bioinformatical Approaches to Reveal Novel T Cell Antigens of Mycobacterium bovis. , 2013, , 73-90.		1
43	Conserved Immune Recognition Hierarchy of Mycobacterial PE/PPE Proteins during Infection in Natural Hosts. PLoS ONE, 2012, 7, e40890.	2.5	53
44	Extended safety and efficacy studies of a live attenuated double leucine and pantothenate auxotroph of Mycobacterium tuberculosis as a vaccine candidate. Vaccine, 2011, 29, 4839-4847.	4.0	46
45	Mycobacterial PE/PPE Proteins at the Host-Pathogen Interface. Clinical and Developmental Immunology, 2011, 2011, 1-11.	3.2	225
46	The Transcriptional Regulator Rv0485 Modulates the Expression of a <i>pe</i> and <i>ppe</i> Gene Pair and Is Required for <i>Mycobacterium tuberculosis</i> Virulence. Infection and Immunity, 2009, 77, 4654-4667.	2.4	33
47	Drying a tuberculosis vaccine without freezing. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 2591-2595.	7.6	90
48	Evolution and expansion of the Mycobacterium tuberculosis PE and PPE multigene families and their association with the duplication of the ESAT-6 (esx) gene cluster regions. BMC Evolutionary Biology, 2006, 6, 95.	3.1	395
49	Stability of Polymorphic GC-Rich Repeat Sequence-Containing Regions of Mycobacterium tuberculosis. Journal of Clinical Microbiology, 2004, 42, 1302-1304.	4.4	6
50	Protection Elicited by a Double Leucine and Pantothenate Auxotroph of Mycobacterium tuberculosis in Guinea Pigs. Infection and Immunity, 2004, 72, 3031-3037.	2.4	149
51	Bacterial genomics and vaccine design. Expert Review of Vaccines, 2003, 2, 437-445.	4.5	5
52	IS6110 Insertions in Mycobacterium tuberculosis: Predominantly into Coding Regions. Journal of Clinical Microbiology, 2001, 39, 3423-3424.	4.4	28
53	Transmission of a Multidrugâ€ResistantMycobacterium tuberculosisStrain Resembling â€œStrain Wâ€• among Noninstitutionalized, Human Immunodeficiency Virusâ€“Seronegative Patients. Journal of Infectious Diseases, 1999, 180, 1608-1615.	3.9	94
54	DNA fingerprinting and molecular epidemiology of tuberculosis: Use and interpretation in an epidemic setting. Electrophoresis, 1999, 20, 1807-1812.	2.9	37